SG11201701565PA - Conjugates comprising cell-binding agents and cytotoxic agents - Google Patents
Conjugates comprising cell-binding agents and cytotoxic agentsInfo
- Publication number
- SG11201701565PA SG11201701565PA SG11201701565PA SG11201701565PA SG11201701565PA SG 11201701565P A SG11201701565P A SG 11201701565PA SG 11201701565P A SG11201701565P A SG 11201701565PA SG 11201701565P A SG11201701565P A SG 11201701565PA SG 11201701565P A SG11201701565P A SG 11201701565PA
- Authority
- SG
- Singapore
- Prior art keywords
- agents
- conjugates
- cell
- cytotoxic
- binding
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 239000002254 cytotoxic agent Substances 0.000 title 1
- 231100000599 cytotoxic agent Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462045264P | 2014-09-03 | 2014-09-03 | |
US201462086986P | 2014-12-03 | 2014-12-03 | |
US201562149379P | 2015-04-17 | 2015-04-17 | |
US201562186235P | 2015-06-29 | 2015-06-29 | |
PCT/US2015/048044 WO2016036794A1 (en) | 2014-09-03 | 2015-09-02 | Conjugates comprising cell-binding agents and cytotoxic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201701565PA true SG11201701565PA (en) | 2017-03-30 |
Family
ID=54147280
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701565PA SG11201701565PA (en) | 2014-09-03 | 2015-09-02 | Conjugates comprising cell-binding agents and cytotoxic agents |
SG10201901825YA SG10201901825YA (en) | 2014-09-03 | 2015-09-02 | Conjugates comprising cell-binding agents and cytotoxic agents |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201901825YA SG10201901825YA (en) | 2014-09-03 | 2015-09-02 | Conjugates comprising cell-binding agents and cytotoxic agents |
Country Status (13)
Country | Link |
---|---|
US (2) | US10988531B2 (en) |
EP (1) | EP3188733B1 (en) |
JP (1) | JP2017529837A (en) |
KR (3) | KR102638901B1 (en) |
CN (1) | CN107580604A (en) |
AU (1) | AU2015312075A1 (en) |
CA (1) | CA2957964A1 (en) |
IL (1) | IL250711A0 (en) |
MA (1) | MA40415A (en) |
RU (1) | RU2017110068A (en) |
SG (2) | SG11201701565PA (en) |
TW (1) | TW201609152A (en) |
WO (1) | WO2016036794A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2741470C9 (en) * | 2014-09-02 | 2021-04-27 | Иммьюноджен, Инк. | Methods for preparing antibody-drug conjugate compositions |
KR102632830B1 (en) * | 2014-09-03 | 2024-02-02 | 이뮤노젠 아이엔씨 | Cytotoxic benzodiazepine derivatives |
JP2017529837A (en) | 2014-09-03 | 2017-10-12 | イミュノジェン・インコーポレーテッド | Complex containing cell binding agent and cytotoxic agent |
EP3253788A4 (en) | 2015-02-06 | 2018-08-08 | Cell IDX, Inc. | Antigen-coupled immunoreagents |
CN114671951A (en) | 2015-06-29 | 2022-06-28 | 伊缪诺金公司 | anti-CD 123 antibodies and conjugates and derivatives thereof |
EP3325482B1 (en) | 2015-07-21 | 2020-06-24 | ImmunoGen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
UY37111A (en) * | 2016-02-05 | 2017-08-31 | Ole Peter Veiby | ANTIBODY AND DRUG CONJUGATES DIRECTED AGAINST GCC |
CN108472371B (en) * | 2016-07-05 | 2022-05-24 | 江苏恒瑞医药股份有限公司 | EGFR antibody-drug conjugate and application thereof in medicine |
KR102580477B1 (en) | 2016-07-22 | 2023-09-19 | 넥타르 테라퓨틱스 | Conjugates of Factor VIII moieties with oxime-containing linkages |
CA3041843A1 (en) * | 2016-11-02 | 2018-05-11 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and parp inhibitors |
PL3558391T3 (en) * | 2016-12-23 | 2022-05-16 | Immunogen, Inc. | Immunoconjugates targeting adam9 and methods of use thereof |
TW202320794A (en) * | 2017-02-28 | 2023-06-01 | 美商伊繆諾金公司 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof |
WO2018183494A1 (en) * | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Cd19-targeting antibody-drug conjugates |
US11566044B2 (en) | 2017-07-26 | 2023-01-31 | The University Of Queensland | Disulfide bond containing compounds and uses thereof |
CN111164208B (en) | 2017-09-29 | 2023-08-04 | 第一三共株式会社 | Antibody-pyrrolobenzodiazepine derivative conjugates |
WO2019104075A1 (en) * | 2017-11-21 | 2019-05-31 | Novartis Ag | Trispecific binding molecules against tumor-associated antigens and uses thereof |
AU2019206587A1 (en) * | 2018-01-12 | 2020-08-06 | Immunogen, Inc. | Methods for antibody drug conjugation, purification, and formulation |
CA3091683A1 (en) | 2018-03-13 | 2019-09-19 | Phanes Therapeutics, Inc. | Anti-folate receptor 1 antibodies and uses thereof |
CN117866095A (en) * | 2018-07-09 | 2024-04-12 | 普众发现医药科技(上海)有限公司 | Folic acid receptor alpha-specific antibodies |
WO2020092631A1 (en) * | 2018-10-31 | 2020-05-07 | Fred Hutchinson Cancer Research Center | Compositions and methods for detecting and treating cancers characterized by expression of mesothelin |
US20210032285A1 (en) * | 2019-03-11 | 2021-02-04 | Cell Idx, Inc. | Methods, compositions, and kits for trapping modified biomolecules |
WO2020187998A1 (en) | 2019-03-19 | 2020-09-24 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer |
WO2020191306A1 (en) * | 2019-03-21 | 2020-09-24 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
CN110922482B (en) * | 2019-12-25 | 2021-08-31 | 源道隆(苏州)医学科技有限公司 | Polypeptide capable of binding CD19 and application thereof |
CN112794911B (en) * | 2021-04-14 | 2021-08-03 | 上海偌妥生物科技有限公司 | Humanized anti-folate receptor 1 antibody and application thereof |
CN113908589B (en) * | 2021-10-08 | 2022-09-27 | 天津工业大学 | Hydrophobic charge induction mode membrane chromatography medium of surface imprinted antibody and preparation method thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
FR2801904B1 (en) | 1999-12-07 | 2002-02-08 | Pasteur Institut | PRODUCTS COMPRISING A SUPPORT ON WHICH NUCLEIC ACIDS ARE FIXED AND THEIR USE AS DNA CHIP |
US7531622B2 (en) | 2002-09-19 | 2009-05-12 | Centre National De La Recherche Scientifique- Cnrs | Synthesis and characterization of novel systems for guidance and vectorization of molecules of therapeutic interest towards target cells |
EP1667708B9 (en) | 2002-12-26 | 2012-10-31 | Mountain View Pharmaceuticals, Inc. | POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY |
GB0305704D0 (en) | 2003-03-13 | 2003-04-16 | Amersham Plc | Radiofluorination methods |
MXPA06014065A (en) | 2004-06-01 | 2007-01-31 | Genentech Inc | Antibody drug conjugates and methods. |
JP2008516621A (en) | 2004-10-18 | 2008-05-22 | ノボ ノルディスク アクティーゼルスカブ | Growth hormone conjugate |
JP5517450B2 (en) | 2005-03-10 | 2014-06-11 | バイオンテック アーゲー | Dimeric or multimeric microproteins |
US20080206151A1 (en) | 2005-04-25 | 2008-08-28 | Alan Cuthbertson | Liposomes |
JP4938263B2 (en) * | 2005-08-19 | 2012-05-23 | 独立行政法人農業生物資源研究所 | Method for inhibiting cytosolic protein function using single-chain antibody and use thereof |
US20070122408A1 (en) | 2005-10-20 | 2007-05-31 | The Scripps Research Institute | Fc Labeling for Immunostaining and Immunotargeting |
FR2897616B1 (en) | 2006-02-20 | 2008-05-30 | Univ Grenoble 1 | PRESENTATION OF REASONS FOR RECOGNITION BY A MULTIVALENT MATRIX GRANTED ON A SOLID SUPPORT |
US7985783B2 (en) * | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
SG183023A1 (en) | 2007-07-16 | 2012-08-30 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
CA2702555A1 (en) | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
WO2009059278A1 (en) | 2007-11-02 | 2009-05-07 | Centocor, Inc. | Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses |
BRPI0911442A2 (en) * | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | potent conjugates and hydrophilic binders |
KR20230044026A (en) | 2010-02-24 | 2023-03-31 | 이뮤노젠 아이엔씨 | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
US9381058B2 (en) * | 2010-11-05 | 2016-07-05 | Ethicon Endo-Surgery, Llc | Recharge system for medical devices |
WO2012112708A1 (en) * | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and methods of preparation |
AR090903A1 (en) * | 2012-05-01 | 2014-12-17 | Genentech Inc | ANTI-PMEL ANTIBODIES AND IMMUNOCADES17 |
SG11201408330XA (en) * | 2012-05-24 | 2015-01-29 | Mountgate Group Ltd | Compositions and methods related to prevention and treatment of rabies infection |
NZ702146A (en) | 2012-06-06 | 2016-11-25 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
US9834597B2 (en) | 2012-09-21 | 2017-12-05 | The Regents Of The University Of California | Modified FC polypeptides, FC conjugates, and methods of use thereof |
WO2014156159A1 (en) * | 2013-03-28 | 2014-10-02 | 東芝ホクト電子株式会社 | Light-emitting device and production method therefor |
WO2014186301A1 (en) | 2013-05-13 | 2014-11-20 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging |
HUE055856T2 (en) * | 2013-08-30 | 2021-12-28 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
EA201691075A1 (en) | 2013-11-26 | 2016-09-30 | Новартис Аг | METHODS OF OXYM CONJUGATION WITH KETON-MODIFIED POLYPEPTIDES |
JP2017529837A (en) | 2014-09-03 | 2017-10-12 | イミュノジェン・インコーポレーテッド | Complex containing cell binding agent and cytotoxic agent |
-
2015
- 2015-09-02 JP JP2017512760A patent/JP2017529837A/en active Pending
- 2015-09-02 KR KR1020237007792A patent/KR102638901B1/en active IP Right Grant
- 2015-09-02 KR KR1020177009020A patent/KR102508023B1/en active IP Right Grant
- 2015-09-02 RU RU2017110068A patent/RU2017110068A/en not_active Application Discontinuation
- 2015-09-02 AU AU2015312075A patent/AU2015312075A1/en not_active Abandoned
- 2015-09-02 WO PCT/US2015/048044 patent/WO2016036794A1/en active Application Filing
- 2015-09-02 SG SG11201701565PA patent/SG11201701565PA/en unknown
- 2015-09-02 MA MA040415A patent/MA40415A/en unknown
- 2015-09-02 US US14/843,429 patent/US10988531B2/en active Active
- 2015-09-02 TW TW104128984A patent/TW201609152A/en unknown
- 2015-09-02 CA CA2957964A patent/CA2957964A1/en not_active Abandoned
- 2015-09-02 SG SG10201901825YA patent/SG10201901825YA/en unknown
- 2015-09-02 CN CN201580059534.4A patent/CN107580604A/en active Pending
- 2015-09-02 KR KR1020247005372A patent/KR20240027148A/en active Application Filing
- 2015-09-02 EP EP15766288.3A patent/EP3188733B1/en active Active
-
2017
- 2017-02-22 IL IL250711A patent/IL250711A0/en unknown
-
2021
- 2021-02-12 US US17/174,911 patent/US11732038B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10988531B2 (en) | 2021-04-27 |
US11732038B2 (en) | 2023-08-22 |
IL250711A0 (en) | 2017-08-31 |
CA2957964A1 (en) | 2016-03-10 |
AU2015312075A1 (en) | 2017-03-09 |
EP3188733B1 (en) | 2019-11-06 |
KR102638901B1 (en) | 2024-02-22 |
KR20170054430A (en) | 2017-05-17 |
EP3188733A1 (en) | 2017-07-12 |
WO2016036794A1 (en) | 2016-03-10 |
RU2017110068A (en) | 2018-10-03 |
KR102508023B1 (en) | 2023-03-10 |
TW201609152A (en) | 2016-03-16 |
KR20240027148A (en) | 2024-02-29 |
MA40415A (en) | 2016-03-10 |
SG10201901825YA (en) | 2019-03-28 |
US20210299271A1 (en) | 2021-09-30 |
RU2017110068A3 (en) | 2019-08-26 |
CN107580604A (en) | 2018-01-12 |
US20160095938A1 (en) | 2016-04-07 |
KR20230039755A (en) | 2023-03-21 |
JP2017529837A (en) | 2017-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250711A0 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
IL290116A (en) | Hydrophilic antibody-drug conjugates | |
HK1231367A1 (en) | Antibody-drug conjugates, their preparation and their therapeutic use | |
IL249647A0 (en) | Targeted conjugates and particles and formulations thereof | |
ZA201604824B (en) | Bifunctional cytotoxic agents | |
HK1219422A1 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
IL248475A0 (en) | Anti-ptk7 antibody-drug conjugates | |
PT3102244T (en) | Antibody-drug conjugates and immunotoxins | |
HUE040517T2 (en) | Antibody-drug conjugates and immunotoxins | |
ZA201608327B (en) | Curcumin-peptide conjugates and formulations thereof | |
HK1219423A1 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
IL258759A (en) | Anti-cd3-folate conjugates and their uses | |
GB201615725D0 (en) | Novel cytotoxic agents and conjugates thereof | |
PT3544637T (en) | Nomv-antigen conjugates and use thereof | |
EP3143036C0 (en) | Par-1 based therapeutic conjugates and uses thereof |